Patents by Inventor Patrick Mailliet

Patrick Mailliet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8980875
    Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: March 17, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Patrick Mailliet, Angela Marinetti, Myriem Skander
  • Publication number: 20130338128
    Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
    Type: Application
    Filed: June 21, 2013
    Publication date: December 19, 2013
    Inventors: Patrick Mailliet, Angela Marinetti, Myriem Skander
  • Patent number: 8481522
    Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: July 9, 2013
    Assignees: Sanofi, Centre National de la Recherche Scientifique
    Inventors: Patrick Mailliet, Angela Marinetti, Myriem Skander
  • Patent number: 8309721
    Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: November 13, 2012
    Assignee: Sanofi
    Inventors: Jean-Marie Ruxer, Victor Certal, Marcel Alasia, Luc Bertin, Herve Minoux, Patrick Mailliet, Frank Halley, Maria Mendez-Perez
  • Patent number: 8163750
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis
    Inventors: Fabienne Thompson, Patrick Mailliet, Jean-Marie Ruxer, Helene Goulaouic, Francois Vallee, Herve Minoux, Fabienne Pilorge, Luc Bertin, Stephane Hourcade, Maria Mendez-Perez, Peter Hamley
  • Publication number: 20120010241
    Abstract: The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R?1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A?), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.
    Type: Application
    Filed: March 18, 2010
    Publication date: January 12, 2012
    Applicant: SANOFI
    Inventors: Luc Bertin, Jean-Christophe Carry, Patrick Mailliet, Herve Minoux, Fabienne Pilorge, Jean-Marie Ruxer
  • Patent number: 8034939
    Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: October 11, 2011
    Assignee: Aventis Pharma S.A..
    Inventors: Patrick Mailliet, Luc Bertin, Didier Benard, Chantal Carrez, François Vallee, Eric Bacque
  • Publication number: 20110172199
    Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
    Type: Application
    Filed: September 2, 2010
    Publication date: July 14, 2011
    Applicants: SANOFI-AVENTIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Patrick MAILLIET, Angela MARINETTI, Myriem SKANDER
  • Publication number: 20110166169
    Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.
    Type: Application
    Filed: September 14, 2010
    Publication date: July 7, 2011
    Applicant: sanofi-aventis
    Inventors: Jean-Marie RUXER, Victor CERTAL, Marcel ALASIA, Luc BERTIN, Herve MINOUX, Patrick MAILLIET, Frank HALLEY, Maria MENDEZ-PEREZ
  • Publication number: 20100130503
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.
    Type: Application
    Filed: November 24, 2009
    Publication date: May 27, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Fabienne THOMPSON, Patrick MAILLIET, Jean-Marie RUXER, Helene GOULAOUIC, François VALLEE, Herve MINOUX, Fabienne PILORGE, Luc BERTIN, Stephane HOURCADE, Maria MENDEZ-PEREZ, Peter HAMLEY
  • Patent number: 7674795
    Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: March 9, 2010
    Assignee: Aventis Pharma SA
    Inventors: Patrick Mailliet, Luc Bertin, Fabienne Thompson, Jean-Marie Ruxer, Fabienne Pilorge, Didier Benard, Hervé Minoux, Chantal Carrez, Hélène Goulaouic, Thierry Gouyon
  • Publication number: 20090226411
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
  • Patent number: 7491710
    Abstract: The present invention relates in particular to novel chemical compounds, particularly to novel organophosphorus derivatives of indazoles, to the compositions containing them, and to the use thereof as medicinal products for treating cancers.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: February 17, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Marie-Pierre Cherrier, Francois Clerc, Alain Commercon, Patrick Mailliet, Hervé Minoux, Bruno Filoche-Rommé
  • Patent number: 7482352
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Patent number: 7435820
    Abstract: Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: October 14, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Fabienne Thompson, Catherine Souaille, Fabrice Viviani, Michel Tabart, Patrick Mailliet, Teresa Damiano, Marie-Pierre Cherrier, Francois Clerc, Frank Halley, Herve Bouchard, Laurence Gauzy-Lazo, Bernard Baudoin
  • Publication number: 20080153837
    Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 26, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Luc BERTIN, Fabienne THOMPSON, Jean-Marie RUXER, Fabienne PILORGE, Didier BENARD, Herve MINOUX, Chantal CARREZ, Helene GOULAOUIC, Thierry GUYON
  • Publication number: 20080119467
    Abstract: Purine derivatives of formula (IA1) or (IB1), compositions containing them and use thereof as medicinal products, in particular in oncology, are described
    Type: Application
    Filed: July 5, 2007
    Publication date: May 22, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Chantal CARREZ, Florence FASSY, Patrick MAILLIET, Fabienne THOMPSON
  • Publication number: 20080119507
    Abstract: This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.
    Type: Application
    Filed: September 28, 2007
    Publication date: May 22, 2008
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick MAILLIET, Luc BERTIN, Didier BENARD, Chantal CARREZ, Francois VALLEE, Eric BACQUE
  • Publication number: 20080108612
    Abstract: This invention relates to methods of inhibiting the Hsp90 chaperone protein, and methods of treatment comprising administration of compounds of formula (IA) (IB) and (II)
    Type: Application
    Filed: July 5, 2007
    Publication date: May 8, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Chantal CARREZ, Florence FASSY, Patrick MAILLIET
  • Publication number: 20080070960
    Abstract: This invention relates to 3-aryl-1,2-benzisoxazole derivatives of formula (I) to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.
    Type: Application
    Filed: August 20, 2007
    Publication date: March 20, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Luc BERTIN, Chantal CARREZ, Fabienne THOMPSON, Patrick MAILLIET, Jean-Marie RUXER